Inflacam 1.5 mg/ml Oral Suspension for Dogs
Meloxicam
Last verified
Veterinary medicinal product: oral suspension. Distribution category: POM-V (Veterinary Medicines Regulations 2013, Schedule 3). Active substance: Meloxicam.1
- Dispensing
- Prescription only1
POM-V: Prescription Only Medicine - Veterinarian. Supplied only on a prescription written by a veterinary surgeon who has assessed the animal.12
Supplied only on a veterinarian's prescription. As stated in the registration decision.
- Animal species
- Dogs1
- Active substance
- Meloxicam
- ATCvet code
- QM01AC063
- Manufacturer
- Marketing authorisation holder: Chanelle Pharmaceuticals Manufacturing Ltd
Withdrawal period
No withdrawal period is set for this drug: it is not intended for food-producing animals.3
Summary of product characteristics
Composition
Each ml contains:
Active substance:
Meloxicam 1.5 mg
Excipients:
| Qualitative composition of excipients and other constituents | Quantitative composition if that information is essential for proper administration of the veterinary medicinal product |
|---|---|
| Sodium benzoate | 5 mg |
| Saccharin sodium | |
| Sodium carboxyl methyl cellulose | |
| Colloidal silicon dioxide | |
| Citric acid monohydrate | |
| Sorbitol solution | |
| Disodium hydrogen-phosphate dodecahydrate | |
| Honey flavour | |
| Purified water |
A yellow coloured suspension.
Pharmacological properties
4.1 ATCvet code: QM01AC06.
4.2 Pharmacodynamics
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
4.3 Pharmacokinetics
Absorption Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 7.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment.
Distribution There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg.
Metabolism Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.
Elimination Meloxicam is eliminated with a half-life of 24 hours. Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.
Target species
Dogs.
Indications
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Dosage
Oral use.
Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.
For longer term treatment, once clinical response has been observed (after ≥ 4 days), the dose of the veterinary medicinal product can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculo-skeletal disorders may vary over time.
To ensure a correct dosage, body weight should be determined as accurately as possible.
The use of suitably calibrated measuring equipment is recommended.
Shake well before use. To be administered orally either mixed with food or directly into the mouth.
The suspension can be given using the measuring syringe provided in the package of the veterinary medicinal product. The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose (i.e. 0.1 mg meloxicam/kg body weight). Thus for initiation of the therapy on the first day, twice the maintenance volume will be required.
A clinical response is normally seen within 3 to 4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent.
Avoid introduction of contamination during use.
Contraindications
Do not use in pregnant or lactating animals.
Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Do not use in dogs less than 6 weeks of age.
Adverse reactions
Dogs:
| Frequency | Adverse events |
|---|---|
| Very rare (<1 animal / 10,000 animals treated, including isolated reports): | Appetite loss, Lethargy, Vomiting, Diarrhoea, Blood in faeces1, Haemorrhagic diarrhoea, Haematemesis, Gastric ulcer, Small intestine ulcer, Large intestine ulcer, Elevated liver enzymes, Renal failure |
1 occult.
These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the package leaflet for respective contact details.
Warnings
Special precautions for safe use in the target species:
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.
This product for dogs should not be used in cats as it is not suitable for use in this species. In cats, Inflacam 0.5 mg/ml oral suspension for cats should be used.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.
3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance
Use during pregnancy, lactation or lay
Pregnancy and lactation:
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Interactions
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. The veterinary medicinal product must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period should however take into account the pharmacokinetic properties of the veterinary medicinal products previously used.
Overdose
In case of overdose, symptomatic treatment should be initiated.
Special warnings
None.
Withdrawal period
Not applicable.
Incompatibilities
None known.
Immediate packaging
Cardboard box containing one 15 ml high-density polyethylene bottle, or 42 ml, 100 ml or 200 ml polyethylene terephthalate bottle.
Each bottle is closed with a polyethylene tamper-evident, child-resistant closure. Each box includes two polypropylene measuring syringes: one for small dogs (up to 20 kg) and one for bigger dogs (up to 60 kg).
Not all pack sizes may be marketed.
Storage
This veterinary medicinal product does not require any special storage conditions.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 2 years. Shelf life after first opening the immediate packaging: 6 months.
Disposal of unused product
Medicines should not be disposed of via wastewater.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.
Additional information
Vm 08749/5010
8 DATE OF FIRST AUTHORISATION
09 December 2011
9 DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS
September 2025
10 CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS
Veterinary medicinal product subject to prescription.
Find more product information by searching for the ‘Product Information Database’ on www.gov.uk.
Approved: 11 December 2025
Registration holder
Chanelle Pharmaceuticals Manufacturing Ltd
Regulations
- Veterinary Medicines Regulations 2013 (SI 2013/2033), Schedule 32